                         SEQUENCE LISTING

<110>  University of Helsinki
 
<120>  NARCOLEPSY-SPECIFIC MARKERS

<130>  31379WO-wp

<160>  13    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  K, R, or H

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  A, V, L, I, P, W, F, or M

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  D or E

<400>  1

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  A, V, L, I, P, W, F, or M

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  any residue

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  any residue

<400>  2

Arg Xaa Xaa Xaa Xaa Xaa Xaa Asp 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  Homo sapiens

<400>  3

Arg Val Leu Ala Pro Ala Leu Asp 
1               5               


<210>  4
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  4

Arg Val Leu Ala Pro Ala Leu Asp Ser Leu Gly Thr 
1               5                   10          


<210>  5
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  5

Arg Val Leu Ala Pro Ala Arg Asp Ser Trp Gly Thr 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  6

Ser Tyr Arg Val Glu Ala Pro Ile Leu Asp Asp Ser 
1               5                   10          


<210>  7
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  7

Arg Val Leu Ala Pro Ala His Asp Ser Trp Gly Thr 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  8

Ser Leu Arg Val Leu Glu Pro Val Met Asp Lys Lys 
1               5                   10          


<210>  9
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  9

Arg His Leu Ala Pro Ala Leu Asp Val Trp Asp Leu 
1               5                   10          


<210>  10
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  10

Arg Val Met Ala Pro Ala Leu Asp Ser Trp Gly Thr 
1               5                   10          


<210>  11
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  11

Arg Val Leu Gly Pro Ala Leu Asp Ser Trp Gly Thr 
1               5                   10          


<210>  12
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  12

Leu Arg Val Ile Ser Pro Thr Leu Asp Ser Met Leu 
1               5                   10          


<210>  13
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide

<400>  13

Gly Arg Asn Leu Ala Pro Ala Gln Asp Thr Ser Ile 
1               5                   10          


